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Abstract
Background: Despite having high cervical cancer incidence and mortality rates, screening for cervical precancerous lesions
remains infrequent in sub-Saharan Africa. The need to screen HIV-positive women because of the higher prevalence and
faster progression of cervical precancerous lesions may be heightened by the increased access to highly-active antiretroviral
therapy (HAART). Policymakers need quantitative data on the effect of HAART and screening to better allocate limited
resources. Our aim was to quantify the potential effect of these interventions on cervical cancer mortality.
Methods and Findings: We constructed a Markov state-transition model of a cohort of HIV-positive women in Cameroon.
Published data on the prevalence, progression and regression of lesions as well as mortality rates from HIV, cervical cancer
and other causes were incorporated into the model. We examined the potential impact, on cumulative cervical cancer
mortality, of four possible scenarios: no HAART and no screening (NHNS), HAART and no screening (HNS), HAART and
screening once on HAART initiation (HSHI), and HAART and screening once at age 35 (HS35). Our model projected that,
compared to NHNS, lifetime cumulative cervical cancer mortality approximately doubled with HNS. It will require 262
women being screened at HAART initiation to prevent one cervical cancer death amongst women on HAART. The
magnitudes of these effects were most sensitive to the rate of progression of precancerous lesions.
Conclusions: Screening, even when done once, has the potential of reducing cervical cancer mortality among HIV-positive
women in Africa. The most feasible and cost-effective screening strategy needs to be determined in each setting.
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Introduction
Cervical cancer is one of the leading causes of cancer death
among women in sub-Saharan Africa [1]. More than 10 million
HIV-infected women also live in this region [2]. Compared to
HIV-negative women, HIV-positive women have a higher
prevalence of cervical precancerous lesions as well as a faster
progression of these lesions to invasive cancer [3–7].
Mortality from cervical cancer and mortality from other HIV-
associated diseases can be competing risks in the evolution of the
other disease. Death from cervical cancer would prevent further
progression of HIV disease and, prior to the advent of highly
active antiretroviral therapy (HAART), the progression of cervical
precancerous lesions to cancer was largely averted by early death
from AIDS and other opportunistic infections. We hypothesize
that the increased survival that is expected to result from increased
access to HAART may be large enough to allow for lesions to
progress to invasive cervical cancer and thus is likely to be followed
by an increase in cervical cancer incidence and mortality.
In developed countries, the potential increase in cervical cancer
mortality in HIV-positive women is curtailed by systematic and
frequent screening in these women [8]. Despite having a higher
HIV prevalence and cervical cancer incidence, screening remains
very infrequent in developing countries presumably because of
resource-limitations. Policymakers need data on the effect of
screening on cervical cancer mortality to better allocate limited
resources.
The long term effect of cervical cancer screening in HIV-
positive women in sub-Saharan Africa, particularly in the era of
HAART remains unknown. Although HAART is expected to
increase cervical cancer mortality while screening is expected to
reduce this mortality, the magnitude of these effects need to be
estimated to better guide policy. In this paper, we estimate the size
the potential effect of HAART therapy with or without screening
on the mortality due to cervical cancer in Cameroon.
Methods
Model structure
We developed a state-transition Markov model, using TreeAge
Pro
TM 2008 Healthcare Module (TreeAge Software Inc.,
Williamstown, MA, USA). This type of model allows analysts
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18527to model transitions of a cohort of patients in a number of health
states over a long period of time subdivided into a series of short
intervals [9]. Our model was designed to simulate the evolution
over time of HIV infection and cervical precancerous and
cancerous lesions in a cohort of HIV-positive women in
Cameroon. The primary structure of the Markov model was
based on a previous description of a model implemented by
Goldie et al, 1999 [10] in HIV-positive women in the US
(Figure 1). In brief, the model summarizes the progression of
cervical neoplasia in HIV in five states: normal with no lesion,
low-grade squamous intra-epithelial lesions (LSIL), high-grade
squamous intra-epithelial lesions (HSIL), invasive cervical cancer
and death. Each of the four (non-death) states is stratified by CD4
cell count. The cancer stage is further stratified by stage of
cervical cancer and whether cancer has been diagnosed (thus
being treated) or not. During their lifetime, women’s disease state
can progress from normal to LSIL to HSIL to cervical cancer.
Women in the HSIL and LSIL states can regress to lower states.
Death can occur to women in any of the four states and can result
from cervical cancer, HIV related-causes or other causes of
death.
Model parameters
Parameters used in the model were abstracted from the
published literature and reflected data for Cameroon as much as
possible. The values used in the baseline model are shown in
Table 1. The base model was designed to simulate the
progression over time of a cohort of HIV-positive women aged
25 with CD4 count .500, 30% of whom had precancerous
lesions (one-third of which were high grade lesions) [11]. All
cause age-specific mortality rates were estimated based on
abridged life tables for women in Cameroon [12]. HIV mortality
rates were estimated based on WHO data [13].The proportion of
HIV-mortality that occurs in each CD4 category was estimated
based on data by Goldie et al [10]. Cervical cancer mortality
rates were also abstracted from WHO estimates of annual
cervical cancer incidence and deaths in Cameroon [1]. Age-
specific mortality rates from other causes were estimated by
adjusting (using another Markov analysis) all-cause age-specific
mortality rates to deduct mortality from cervical cancer and
mortality from HIV.
In the absence of published data on long-term progression or
regression rates of precancerous lesions in HIV positive women in
Cameroon, we used published estimates from women in the pre-
HAART era from Goldie et al [10]. The effect of HAART on
HIV/AIDS-related mortality was also estimated based on the
published literature [14,15].
Model assumptions
Key simplifying assumptions of the model include: 1) The natural
history of cervical cancer involves progress from normal to LSIL to
HSIL to local cancer to regional/distant cancer to death from
cancer, without skipping. 2) The regression of neoplasia can only be
from HSIL to normal or LSIL, of from LSIL to normal. A patient
cannot regress from cancer. Cancer stages also cannot regress. 3)
HIV diseases progression is only from CD4 500+ to 200–500 to
,200. This is a historic parameter, indicating the advance in HIV
disease. Once a patient has CD4 ,200 she will always be classified
in the CD4 ,200 category, even if her actual CD4 count improved
with treatment. In other words worsening HIV-disease cannot
regress. This assumption is consistent with data that show that
improvements in antiretroviral therapy do not appear to reduce the
progression of precancerous lesions even amongst women with
improved CD4 counts [16]. 4) The progression/regression rate of
cervical precancerous lesions is not dependent on a previous history
of precancerous lesions as the parameters used in the model are
from heterogeneous populations (that include patients with and
without a previous history of lesions) [17].
Scenarios and outcomes assessed
We assessed the projected lifetime cumulative mortality due to
cervical cancer in four plausible scenarios of HIV and cervical
cancer care in Cameroon: no HAART and no screening (NHNS),
HAART when indicated and no screening (HNS), HAART when
indicated and screening on HAART initiation (HSHI), and
HAART when indicated and a single screen at age 35. The age
35 was selected based on WHO recommendations for screening in
resource-limited settings [18].
Figure 1. Summary of states in the Markov model. Adapted from an original depiction by Goldie et al, 1999 [10].
doi:10.1371/journal.pone.0018527.g001
Cervical Cancer Deaths in HIV
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The sensitivity of cumulative cervical cancer mortality to
parameter estimates was analyzed in one-way sensitivity analyses.
We were particularly interested in the sensitivity of HAART
effectiveness in lowering HIV-mortality and SIL progression rates
since the baseline values used were all external to the study and
these values are likely to vary substantially depending on the study
population.
Results
Base model
A substantial proportion of women were expected to die from
cervical cancer. The baseline model projected a lifetime
cumulative cervical cancer mortality of 25.4 per 1000 HIV-
positive women who were infected at age 25 and neither received
HAART nor were screened for cervical cancer (Table 2).
Cumulative cervical cancer mortality doubled to 46.6 per 1000
HIV-positive women who were infected at age 25, were placed on
HAART when their CD4 went below 200cells/mm3 and had no
screening for cervical cancer. If the latter women were screened
either once at HAART initiation or once when they were aged 35,
then mortality could reduce to 42.8 and 41.7 per 1000 women
respectively. Interestingly, cervical cancer mortality following
HAART and screening once at HAART initiation was still higher
than cervical cancer mortality associated with no HAART and no
screening.
In absolute measures, these mortality projections meant that
compared to no HAART and no screening, an additional cervical
cancer death would occur for every 47 women put on HAART
when indicated, but not screened. Conversely, once women were
Table 1. Baseline parameters used in modeling cervical cancer mortality in HIV positive women.
Variable CD4 .500
CD4
200–500
CD4
,200
Source
(reference)
Initial prevalence of lesions, % 30 NA NA [11]
Initial proportion of lesions that were HSIL (%) 33 NA NA [11]
HIV infection
HIV mortality rate (per 1000 per year)* 0.05 6.06 48.6 [13]
Effect of HAART in reducing HIV mortality NA NA 4-fold [14,15]
HIV progression rate (per 100 per year)** 18.1 27.5 NA [10]
Cervical Cancer
Cancer mortality rate (per 1000 per year)* [1]
Local invasive cancer 41.1 41.1 41.1
Regional invasive cancer 222.1 222.1 222.1
Distant invasive cancer 543.5 543.5 543.5
Progression rate (per 100 per year) [10]
Normal to LSIL 0.016 0.67 0.67
LSIL to HSIL 0.73 2.93 2.93
HSIL to local invasive cancer 2.0 2.42 2.42
Local to regional invasive cancer 4.03 4.03 4.03
Regional to distant invasive cancer 4.03 4.03 4.03
Regression rate (per 100 per year) [10]
LSIL to normal 2.99 2.99 2.99
HSIL to LSIL 0.30 0.30 0.30
HSIL to normal 0.30 0.30 0.30
Screening test [10]
Sensitivity, % 70 70 70
Specificity, % 90 90 90
*Mortality in each CD4 category or cervical cancer stage were determined by weighting crude estimates by the proportions due to each category or stage from Goldie
et al,1999 [10].
**estimated from mean duration at each stage.
doi:10.1371/journal.pone.0018527.t001
Table 2. Projected cumulative (lifetime) cervical cancer
mortality in HIV-positive women in Cameroon on HAART and
or screened for cervical cancer.
Intervention Mortality per 1000 NNT NNS
No HAART, No Screen 25.4 Ref. -
HAART, No Screen 46.6 47 Ref
HAART+ Screen once at HAART
initiation
42.8 - 262
HAART+ Screen once at age 35 41.7 - 202
NNT - Number of women who need to receive HAART for each additional
cancer death.
NNS - Number of women who need to be screened for each cancer death
prevented.
Ref: Referent.
doi:10.1371/journal.pone.0018527.t002
Cervical Cancer Deaths in HIV
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initiation would prevent one case of cancer for every 262 women
screened. Screening once at age 35 was projected to prevent one
cancer death per 202 women screened.
The timing of cervical cancer deaths was also influenced by the
type of intervention received (Figure 2). With NHNS the majority
of cervical cancer deaths occurred within the second and third
decade after diagnosis. In patients on HAART the occurrence of
deaths was further delayed beyond the third decade after infection.
Only HAART had a substantial impact on the overall survival
from all causes of death after infection (Figure 2 and Table 3).
Compared to no HAART and no screening, all three scenarios
Figure 2. Cumulative mortality by intervention in a cohort of HIV positive women getting infected at age 25. A. Cumulative mortality
from cervical cancer. B. Cumulative mortality from all causes (NHNS: No HAART No Screening; HNS: HAART but No Screening; HSHI: HAART and one
screen at HAART initiation; HS35: HAART and one screen at age 35).
doi:10.1371/journal.pone.0018527.g002
Cervical Cancer Deaths in HIV
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screen at HAART initiation and HAART with one screen at age
35) resulted in gains in life-expectancy. However, there was only
minimal difference in survival from all causes under the three
scenarios with HAART, with one time screening only slightly
increasing survival (Table 3).
Sensitivity analysis
The projected cervical cancer mortality estimates were robust to
the magnitude of the effect of HAART in reducing HIV-related
mortality (Figure 3). All four mortality estimates were within 10%
of their baseline value unless the effect of HAART was below a
two-fold decrease in HIV mortality. Further increasing the effect
of HAART only slightly increased cumulative cervical cancer
mortality.
Mortality estimates were most sensitive to the rate of
progression of precancerous lesions to more severe lesions or
invasive cancer (Figure 3). In all four scenarios cumulative
mortality increased with faster progression rates. Doubling the
progression rate resulted in a near doubling of cervical cancer
mortality. Nevertheless, the relative mortality between each of the
scenarios remained constant across progression rates.
In contrast to the sensitivity of the model to the progression rate
of lesions, the model mortality estimates were rather robust to
other parameters such as cancer mortality rates and other baseline
parameters. The cumulative cervical cancer mortality only slightly
increased with increases in cervical cancer mortality rates
(Figure 3). Cumulative cervical cancer mortality was also robust
to the baseline prevalence of lesions (Figure 4) and the proportion
of lesions that were high grade lesions (Figure 4). As expected,
mortality from cervical cancer decreased as the age of HIV
infection (the initial age) of the cohort increased (Figure 4).
Screening test sensitivity had very little impact on cervical cancer
mortality with mortality only slightly decreasing as sensitivity
increased. Life expectancy also increased only slightly with
improved sensitivity - a gain of 0.06 years as sensitivity increased
from 50% to 100%. Screening test specificity had no impact on
cervical cancer mortality or life expectancy.
Discussion
The magnitude and the impact of HAART treatment and
screening, on cervical cancer mortality in HIV-positive women in
sub-Saharan Africa remain unknown. The ethical and practical
complexities of potentially denying care to patients and following
women for their lifetime respectively make it unfeasible to conduct
a study to quantify this impact. Computer-based simulation
models, however, provide an alternative means of quantifying the
potential impact of these interventions. These models are of even
greater importance in sub-Saharan Africa, where real-life
estimation is hampered by limitations in the long-term follow-up
of patients, in cancer diagnosis and in the determination of cause
of death.
In this paper, we used a mathematical model to project that
mortality due to cervical cancer in HIV positive women in Africa
is potentially very high. While this mortality can be worsened by
providing HAART without screening, screening can be associated
with non-negligible reductions in mortality from cervical cancer.
These data confirm and quantify the potential gains of cervical
cancer screening in HIV-positive women in regions with high
cancer incidence and mortality such as Cameroon. With an
estimated 200,000 HIV-infected women in Cameroon [12], our
projections imply that screening these women once at HAART
initiation would prevent close to 763 deaths due to cervical cancer,
while screening these women once at age 35 could prevent
approximately 990 deaths in these women.
WHO guidelines for screening in resource-limited settings
include at least a one-time screening in the third or fourth decade
of life [17]. Our projected potential gains with one-time screening
in HIV-positive women are much smaller than those in other
settings where screening is systematic and more frequent. For
example, screening in the UK was estimated to prevent one death
for every 65 women screened systematically [19]. The reductions
in cervical cancer mortality associated with a single screen in HIV-
positive women were also less compared to the estimated 25–36%
reductions in lifetime risk reported in models of HIV-negative
women in five other developing countries [20]. These differences
could be due to a higher incidence and faster progression of
precancerous lesions in HIV-positive women compared to HIV-
negative women [7].
Although we show potential benefits of screening, our analysis
did not take the cost of screening into account. A formal
assessment of the cost-effectiveness of screening in this and other
settings will provide additional information regarding resource
needs and potential effects for cervical cancer screening. Our data
show that even one time screening at HAART initiation or at age
35 would potentially be beneficial. According to guidelines from
the Commission on Macroeconomics and Health, a policy is
generally considered cost-effective if the incremental cost per life
saved is less than the country’s GDP per capita [21]. Our analyses
estimate that one-time screen policies would improve life
expectancy by approximately 0.10 years. With Cameroon’s
GDP per capita being estimated at USD 1,019 [22], we further
estimated that a one-time screening strategy will need to cost at
most 101 USD per screen for it to be considered cost-effective.
This cost estimates includes both direct costs (such as cost of the
Table 3. Projected cumulative cause of mortality and gains in life expectancy in HIV-positive women in Cameroon on HAART and
or screened for cervical cancer.
Intervention Cause of mortality (proportion) Gains in life expectancy (years)
HIV/AIDS
Cervical
cancer Other cause Due to HAART Due to Screening
No HAART, No Screen 63.3% 2.5% 34.1% Ref. -
HAART, No Screen 28.3% 4.7% 66.8% 10.6 Ref.
HAART+ Screen once at HAART initiation 28.4% 4.3% 67.1% - 0.09
HAART+ Screen at age 35 28.4% 4.2% 67.2% - 0.11
Ref: Referent.
doi:10.1371/journal.pone.0018527.t003
Cervical Cancer Deaths in HIV
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e18527Figure 3. Sensitivity of cumulative cervical cancer mortality to model parameters. A. Sensitivity to the relative effect of HAART in reducing
HIV-mortality. B. Sensitivity to the progression rate of precancerous lesions. C. Sensitivity to cervical cancer mortality rate. The values on the x-axis
refer to the ratio of each parameter compared to its value in the base model. (NHNS: No HAART No Screening; HNS: HAART but No Screening; HSHI:
HAART and one screen at HAART initiation; HS35: HAART and one screen at age 35).
doi:10.1371/journal.pone.0018527.g003
Cervical Cancer Deaths in HIV
PLoS ONE | www.plosone.org 6 April 2011 | Volume 6 | Issue 4 | e18527Figure 4. Sensitivity of cumulative cervical cancer mortality to baseline parameters. A. Sensitivity to the prevalence of squamous
intraepithelial lesions at beginning of cohort. B. Sensitivity to the proportion of lesions that are high grade squamous intraepithelial lesions at the
beginning of cohort. C. Sensitivity to the initial age of cohort. (NHNS: No HAART No Screening; HNS: HAART but No Screening; HSHI: HAART and one
screen at HAART initiation; HS35: HAART and one screen at age 35).
doi:10.1371/journal.pone.0018527.g004
Cervical Cancer Deaths in HIV
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program). More formal cost-effectiveness analyses including
appropriate weighting for disability and discounting will be
needed to confirm this.
As with every simulation exercise, the model form, parameters
and assumptions present potential limitations to the confidence
with which inferences from the analysis can be made to real-life
scenarios. We choose a model that had previously been validated
in the immediate pre-HAART era, a population similar to our
target in this analysis. However some of the model parameters
which could not be directly estimated were estimated indirectly
using either US or WHO data. In the absence of prospective data
on cervical cancer progression and regression rates for Camer-
oonian women, we used published data from the pre-HAART era
in the US and assessed the impact of this choice in sensitivity
analyses. A faster progression rate in developing countries could
translate to even higher mortality due to cervical cancer.
Nevertheless, the relative effects of HAART and screening were
projected to remain similar, while the number of deaths averted
with screening would increase as progression rates increase. On
the other hand, if HAART was shown to have an effect on the
progression of lesions, a finding that has been inconsistent [15],
then the mortality due to cancer as well as the gains associated
with screening would be reduced.
A further limitation, by design, of this analysis is the absence of
any consideration for HPV infection status and/or HPV vaccines.
The former was due to the absence of reliable data on HPV and
the progression of lesions in HIV in sub-Saharan Africa. It is thus
difficult to infer on the potential impact of an HPV test. We
however suspect that one-time screening with an HPV-test could
be better than a one-time cytology screen, as the HPV test will
have a higher sensitivity, be able to detect lesions at earlier stages
(allowing for early treatment) and thus result in lower mortality.
Indeed, a recent study in population (of mainly HIV-negative
women) in rural India reported a 50% reduction in cervical cancer
mortality (measured as hazards of mortality) following a one-time
HPV test [23]. They also report a low insignificant reduction in
mortality with cytology and VIA. These findings however need to
be verified in a population of HIV-positive women, in whom the
greater variability of HPV types, higher HPV-persistence rates and
faster progression of lesions could mean reduced effect of an HPV
test used for one-time screening.
While cervical cancer screening could substantially reduce
mortality due to cervical cancer, it was projected to have very little
effect on all cause mortality. We did not assess the quality of life
gains, but these data indicate that even with screening further
gains in overall life expectancy will depend on the extent of
prevention and care for other causes of mortality including
opportunistic infections.
In conclusion, cervical cancer could account for a high
proportion of deaths among HIV- positive women in Africa once
they have access to HAART. These deaths could be reduced with
screening, even when done just once. Antiretroviral treatment
scale-up activities need to be followed by strategies to systemat-
ically increase access to screening services as well as treatment for
cervical precancerous and cancerous lesions as needed. While the
feasibility and cost-effectiveness of more frequent screening is still
to be assessed, women need to be provided the opportunity to get
screened at least once on initiating HAART or at age 35.
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